atenolol has been researched along with ramipril in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (20.00) | 18.2507 |
| 2000's | 14 (35.00) | 29.6817 |
| 2010's | 17 (42.50) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kendall, FD; Lenox-Smith, AJ; Street, RB | 1 |
| Breitstadt, A; Erhard, W; Krall, H; Lindner, U; Pfeiffer, C | 1 |
| Balasia, BA; Berger, DS; Cholley, BP; Jain, S; Korcarz, C; Lang, RM; Marcus, RH; Murphy, MB; Sandelski, J; Shroff, SG | 1 |
| Berger, E; Braun, N; Erley, CM; Heyne, N; Klass, M; Krämer, D; Risler, T; Wolf, S | 1 |
| Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C | 1 |
| Agabiti-Rosei, E; Ambrosioni, E; Dal Palù, C; Muiesan, ML; Zanchetti, A | 1 |
| Berger, ED; Braun, N; Erley, CM; Heyne, N; Klass, M; Krämer, D; Risler, T; Wolf, S | 1 |
| Fraser, T; Li, M; Turner, SW; Wen, C; Whitworth, JA | 1 |
| Betekhtina, VA; Rakov, SS | 1 |
| Armentano, RL; Baglivo, H; Brandani, L; Espinosa, JD; Graf, S; Ramírez, AJ; Sánchez, R | 1 |
| Brainin, M; Finsterer, J; Slany, J; Stöllberger, C | 1 |
| Adji, A; Hirata, K; O'Rourke, MF; Vlachopoulos, C | 1 |
| Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D | 1 |
| Eveson, JW; Oxley, JD; Robinson, CM; Weir, J | 1 |
| Coelho, EB; da Silva, CA; Fazan, R; Nobre, F; Salgado, HC | 1 |
| Cao, G; Grana, D; Milei, J; Toblli, JE | 1 |
| Boccioletti, V; Cominacini, L; Fabrizzi, P; Garbin, U; Lo Cascio, V; Luchetta, ML; Nava, MC; Pasini, AF; Pellegrini, M; Stranieri, C | 1 |
| Adji, A; Hirata, K; Hoegler, S; O'Rourke, MF | 1 |
| Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Quon, MJ; Shin, EK | 1 |
| Afzal, R; Pais, P; Pogue, J; Sigamani, A; Xavier, D; Yusuf, S | 1 |
| Afzal, R; Eikelboom, J; Gupta, R; Mohan, V; Pais, P; Sigamani, A; Teo, K; Thomas, N; Xavier, D; Yusuf, S | 1 |
| Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T | 1 |
| Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO | 1 |
| Afzal, R; Gao, P; Pais, P; Sigamani, A; Teo, KK; Xavier, D; Yusuf, S | 1 |
| Bautista, LE; Casas, JP; Chirinos, JA; Ferrante, D; Ferreccio, C; Herrera, VM; Medina-Lezama, J; Miranda, JJ; Oróstegui Arenas, M; Pérez, CM; Pichardo, R; Sánchez Abanto, JR; Schapochnik, N; Silva, E; Vera-Cala, LM | 1 |
| Agarwal, M; Chugh, PK; Gupta, M; Tekur, U | 1 |
| Azizi, M; Blanchard, A; Charbit, B; Ezan, E; Funck-Brentano, C; Ménard, J; Peyrard, S; Wuerzner, G | 1 |
| Bhadada, SV; Patel, BM | 1 |
| Galantine, V; Gosse, P; Lacraz, A; Rubin, S | 1 |
| Alexander, MR; Burley, JC; Khaled, SA; Roberts, CJ; Yang, J | 1 |
| Cheruvu, HS; Devalapalli, MMR; Sampathi, S; Shivakumar, S; Veeravalli, VB; Yertha, T | 1 |
| Bosch, J; Dans, AL; Gamra, H; Gao, P; Joseph, P; Lopez, PC; Lopez-Jaramillo, P; Pais, P; Santoso, A; Talukder, S; Teo, K; Tyrwhitt, J; Xavier, D; Yeates, K; Yusoff, K; Yusuf, S | 1 |
| Gaziano, TA; Jardim, TV; Ogden, JM; Pandya, A; Rodgers, A; Sy, S; Weinstein, MC | 1 |
| Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS; Serag, A | 1 |
2 review(s) available for atenolol and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Simvastatin; Stroke | 2012 |
19 trial(s) available for atenolol and ramipril
| Article | Year |
|---|---|
Comparison of ramipril against atenolol in controlling mild-to-moderate hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Bridged Bicyclo Compounds; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Ramipril | 1991 |
Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Bridged Bicyclo Compounds; Diabetes Complications; Double-Blind Method; Drug Interactions; Humans; Hypertension; Hypoglycemic Agents; Middle Aged; Ramipril; Retrospective Studies; Single-Blind Method | 1991 |
Differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetics in African-American patients.
Topics: Administration, Oral; Analysis of Variance; Antihypertensive Agents; Atenolol; Black People; Cross-Over Studies; Double-Blind Method; Echocardiography; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nifedipine; Ramipril; Time Factors; Ultrasonography, Doppler; Ventricular Function, Left | 1995 |
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Celiprolol; Chronic Disease; Double-Blind Method; Female; Glomerulonephritis; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Ramipril; Renal Circulation; Vasodilator Agents | 1996 |
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.
Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Felodipine; Female; Humans; Kidney; Male; Middle Aged; Prospective Studies; Ramipril; Vasodilator Agents | 1996 |
ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Echocardiography; Female; Heart; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ramipril; Systole; Ventricular Function, Left | 1995 |
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Celiprolol; Chronic Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Glomerulonephritis; Humans; Inulin; Male; Middle Aged; p-Aminohippuric Acid; Proteinuria; Ramipril; Renal Circulation; Renal Plasma Flow, Effective; Treatment Outcome | 1997 |
Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Brachial Artery; Compliance; Double-Blind Method; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Ramipril | 2001 |
Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta; Atenolol; Blood Flow Velocity; Blood Pressure; Brachial Artery; Female; Humans; Hypertension; Male; Middle Aged; Placebos; Pulsatile Flow; Ramipril | 2005 |
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Captopril; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium; Propranolol; Ramipril; Transforming Growth Factor beta1 | 2006 |
Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Blood Pressure; Captopril; Cell Adhesion Molecules; Cholesterol, HDL; Endothelium, Vascular; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Ramipril; Sulfhydryl Compounds; Triglycerides; Vasodilation | 2007 |
Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Blood Pressure Determination; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Prognosis; Radial Artery; Ramipril; Risk Factors; Systole | 2007 |
Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.
Topics: Adipokines; Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Benzimidazoles; Biphenyl Compounds; Cholesterol, HDL; Comorbidity; Endothelium, Vascular; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Single-Blind Method; Tetrazoles; Triglycerides | 2010 |
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Capsules; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Research Design; Secondary Prevention; Simvastatin; Treatment Outcome | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Risk Reduction Behavior; Simvastatin; Treatment Outcome | 2009 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolol; Biological Availability; Capsules; Cardiovascular Diseases; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Simvastatin; Tandem Mass Spectrometry; Young Adult | 2010 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Capsules; Cardiovascular Diseases; Cholesterol, LDL; Creatinine; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; India; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Potassium; Ramipril; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2012 |
Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Chromatography, Liquid; Cross-Over Studies; Diet, Sodium-Restricted; Dose-Response Relationship, Drug; Electrocardiography; Humans; Immunoradiometric Assay; Male; Ramipril; Reference Values; Renin; Renin-Angiotensin System; Sodium, Dietary; Tetrazoles; Treatment Outcome; Young Adult | 2013 |
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Female; Global Health; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Primary Prevention; Ramipril; Retrospective Studies; Simvastatin | 2018 |
19 other study(ies) available for atenolol and ramipril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Haemodynamic mechanisms of corticotropin (ACTH)-induced hypertension in the rat.
Topics: Adrenocorticotropic Hormone; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiac Output; Energy Metabolism; Hypertension, Renal; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Renal Circulation; Splanchnic Circulation; Vascular Resistance | 1999 |
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Apolipoproteins; Atenolol; Biomarkers; Complement C3; Complement C4; Female; Haptoglobins; Humans; Hypertension; Immunoglobulin G; Immunoglobulins; Isradipine; Kidney; Male; Middle Aged; Models, Theoretical; Monitoring, Physiologic; Prealbumin; Proteinuria; Ramipril; Transferrin | 2000 |
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Losartan; Ramipril; Stroke | 2003 |
Lichenoid and granulomatous stomatitis: an entity or a non-specific inflammatory process?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Atenolol; Drug Combinations; Drug Eruptions; Drug Hypersensitivity; Female; Granuloma; Humans; Lichen Planus, Oral; Male; Middle Aged; Mouth Mucosa; Naproxen; Ramipril; Stomatitis | 2006 |
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Autonomic Nervous System; Blood Pressure; Cardiovascular System; Heart Rate; Hydrochlorothiazide; Hypertension; Losartan; Male; Ramipril; Rats; Rats, Wistar; Sympathetic Nervous System | 2006 |
Effects of ACE inhibition and beta-blockade on plasminogen activator inhibitor-1 and transforming growth factor-beta1 in carotid glomus and autonomic ganglia in hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Carotid Body; Disease Models, Animal; Extracellular Matrix; Ganglia, Autonomic; Hypertension; Male; Plasminogen Activator Inhibitor 1; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Time Factors; Transforming Growth Factor beta1 | 2007 |
A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
Topics: Aged; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Developing Countries; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Latin America; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors | 2013 |
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.
Topics: Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Blood Pressure; Cyclooxygenase 2 Inhibitors; Desoxycorticosterone Acetate; Disease Models, Animal; Etoricoxib; Hypertension; Mineralocorticoids; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Sodium Chloride; Sulfones; Telmisartan | 2013 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Metoprolol; Perindopril; Ramipril; Rats, Wistar; Spironolactone | 2014 |
Malignant hypertension and interferon-beta: a case report.
Topics: Adult; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Bisoprolol; Female; Humans; Hypertension, Malignant; Immunologic Factors; Interferon-beta; Irbesartan; Multiple Sclerosis; Ramipril; Renin-Angiotensin System; Tetrazoles | 2014 |
3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles.
Topics: Aspirin; Atenolol; Delayed-Action Preparations; Drug Combinations; Drug Liberation; Excipients; Hydrochlorothiazide; Powder Diffraction; Pravastatin; Printing, Three-Dimensional; Ramipril; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; X-Ray Diffraction | 2015 |
Hansen solubility parameters for assay method optimization of simvastatin, ramipril, atenolol, hydrochlorothiazide and aspirin in human plasma using liquid chromatography with tandem mass spectrometry.
Topics: Aspirin; Atenolol; Chromatography, Liquid; Humans; Hydrochlorothiazide; Ramipril; Reproducibility of Results; Simvastatin; Solubility; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2017 |
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Topics: Adrenergic beta-Antagonists; Aspirin; Atenolol; Budgets; Cardiovascular Diseases; Cost Savings; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Medication Adherence; Middle Aged; Nutrition Surveys; Platelet Aggregation Inhibitors; Ramipril; Renin-Angiotensin System; Secondary Prevention; Stroke; United States | 2019 |
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.
Topics: Algorithms; Aspirin; Atenolol; Capsules; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Least-Squares Analysis; Ramipril; Simvastatin; Spectrophotometry, Ultraviolet | 2020 |